Scott Bembenek has a PhD in theoretical chemical physics, was a National Research Council Fellow, and is an expert drug discovery scientist with over 18 years in industry drug discovery and computational chemistry. In that time, he has been a key member of the teams that developed several clinical candidates; developed a computational approach that – within only two years – resulted in a clinical candidate for oncology (currently entering Phase 2), and has been a leader on multiple high-profile projects from hit identification to clinical candidacy. Currently, he is the Founder and CEO of Denovicon Therapeutics, which uses their proven computational platform, state-of-the-art hardware infrastructure, and proprietary AI–molecular modeling algorithm to accelerate and improve the development of small-molecule therapeutics.
Ton VAN DAELEN is the Life Sciences Portfolio Lead at BIOVIA / Dassault Systèmes. He has helped pharmaceutical and biotech customers implement cloud solutions to address internal and external research collaboration challenges. Previously, Ton helped grow the Pipeline Pilot product in various support and product management functions and grow it into one of the premier research informatics frameworks in biopharma organizations. Today one of Ton’s interests is using this framework for building solutions that leverage AI and Machine Learning for the design of novel therapeutics. This helps pharma save significant cost in the discovery phase and get new drugs to market faster. Ton has a Ph.D. in theoretical chemistry from the University of Eindhoven, The Netherlands.